This site is intended for UK healthcare professionals

 

Featured videos #1 videos

In this masterclass, Dr Dermot Neely and Dr Jai Cegla discuss the why, when and how of measuring lipoprotein(a) [Lp(a)], the current management of people with elevated Lp(a) and the future prospects for treatment.
Jon Byrne and Madalina Garbi explore the latest guidelines and current practice around transcatheter valve interventions (including aortic valve implantation (TAVI), mitral regurgitation management and tricuspid valve repair) – which patients are suitable for these interventions, and how do they compare to traditional surgical approaches?
Dr Paul Foley and Prof Terry McCormack share the key changes in the new ESC guidance on atrial fibrillation, hypertension and arterial disease.

AstraZeneca has provided a sponsorship towards this independent programme. AstraZeneca has had no editorial input into or control over the agenda, content development or choice of speakers, nor opportunity to influence except for the AstraZeneca sponsored symposia presentations. The remainder of the programme has remained under the full editorial control of the British Journal of Cardiology.

Dr Sarah Birkhoelzer and Dr Aaron Henry discuss hot topics and late-breaking abstracts from across the congress.

AstraZeneca has provided a sponsorship towards this independent programme. AstraZeneca has had no editorial input into or control over the agenda, content development or choice of speakers, nor opportunity to influence except for the AstraZeneca sponsored symposia presentations. The remainder of the programme has remained under the full editorial control of the British Journal of Cardiology.

In this masterclass, Alison Pottle and Jai Cegla provide discuss screening for familial hypercholesterolaemia (FH), treatment advances in dyslipidaemia, the role of lipid apheresis in specific populations and the importance of patient education.
Professor Paul Kalra summarises key findings presented at the 2024 Heart Failure Association ESC meeting in Lisbon. He discusses the new data on hypertrophic cardiomyopathy, heart failure with reduced ejection fraction, and challenges in diagnosis and treatment optimisation. He also explores the early benefits of sodium-glucose co-transporter 2 inhibitors and evidence-based treatments for heart failure with preserved ejection fraction.
Many of us understand the importance of exercise to improve not only our cardiovascular health, but health in general. Despite healthier living, cardiac-related injury or even death can occur in those who appear physically healthy, even athletes. Join Dr Gherardo Finocchiaro as he discusses the aetiology and epidemiology of sudden cardiac death, and the importance of cardiac screening, diagnosis and risk minimisation.
Watch Terry McCormack and Peter Green discuss the national guidelines for primary and secondary prevention of cardiovascular disease (CVD), risk assessment and recommended lipid targets for CVD, and the availability of smart open-access data tools that can reduce health inequalities and improve treatment outcomes for your patients.
 

Thanks for your feedback. Please note that by including your email address, you are giving permission for us to contact you by email to help resolve any issues.